NL-OMON30793尚未招募2 期
Glivec (imatinib mesylate) in systemic sclerosis, a pilot study - Glivec in systemic sclerosis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •· Patients with systemic sclerosis (either diffuse or limited) refractory to standard therapy
- •· Adequate end organ function, defined as: total bilirubin <1.5 x ULN, SGOT and SGPT < 2.5 x ULN (or <5 x ULN if hepatic disease involvement is present), creatinine < 1.5 x ULN, ANC >1.5 x 109/L, platelets > 100 x 109/L.
- •· Adequate anticonception in women
- •· Written informed consent
排除标准
- •· Age < 18 years
- •· Previous or current malignancy
- •· Current treatment with endothelin receptor antagonist
- •· Current treatment with immunosuppressive drugs
- •· Life expectancy < 6 months
- •· Pregnancy
- •· Inability to adhere to the current protocol
研究者
相似试验
进行中（未招募）
不适用
Glivec (imatinib mesylate) in systemic sclerosis, a pilot study - Glivec in systemic sclerosissystemic sclerosisMedDRA version: 9.1Level: LLTClassification code 10039710Term: SclerodermaEUCTR2006-007091-15-NLErasmusMC10
已完成
2 期
Phase2 Study of Glivec (imatinib mesylate, formerly known as STI571) in Patients with Relapsed or Refractory Sarcomas with c-kit or PDGFR ExpressioJPRN-jRCT1091220003Office of Imatinib phase 2 study40
已完成
2 期
Phase2 Study of Glivec (imatinib mesylate, formerly known as STI571) in Patients with Relapsed or Refractory Sarcomas with c-kit or PDGFR ExpressioSarcoma with c-kit or PDGFR expression by immunohistochemistryJPRN-C000000073Office of Imatinib phase2 study40
已完成
1 期
Imatinib in Systemic SclerosisScleroderma, SystemicNCT00506831Stanford University9
已完成
2 期
Glivec plus chemotherapy in blast-phase CML and Ph+ ABlast-Phase Chronic Myeloid LeukemiaPhiladelphia Chromosome-Positive Acute Lymphoblastic LeukemiaCancer - Leukaemia - Acute leukaemiaCancer - Leukaemia - Chronic leukaemiaACTRN12605000072617Australasian Leukaemia and Lymphoma Group41